For neurologists, psychiatrists, and healthcare investors, insomnia treatment has evolved from barbiturates to safer alternatives. Barbiturates carry high risks of respiratory depression, dependence, and overdose. The solution is Glutethimide—a hypnotic sedative drug that is a safe alternative to barbiturates for the treatment of insomnia. It is primarily used to help patients feel sleepy and calm. Glutethimide is highly lipophilic, concentrating in adipose tissue and the brain. It undergoes extensive metabolism in the liver, with both unconjugated and conjugated metabolites excreted by the kidneys. Beyond insomnia, glutethimide is also used to prevent jaundice in newborns and reduce muscle tremors. However, as a Schedule II drug under psychotropic substances (high abuse potential), its distribution is strictly controlled. This report analyzes this specialized sedative-hypnotic segment, projected to grow at 5.9% CAGR through 2031.
According to the latest release from global leading market research publisher QYResearch, *”Glutethimide – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032,”* the global market for Glutethimide was valued at US$ 3,846 million in 2024 and is forecast to reach US$ 5,713 million by 2031, representing a compound annual growth rate (CAGR) of 5.9% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670547/glutethimide
Product Definition – Pharmacology, Indications, and Safety Profile
Glutethimide is a hypnotic sedative drug that serves as a safe alternative to barbiturates for the treatment of insomnia. It is primarily used to induce sleepiness and calmness in patients.
Pharmacological Properties:
- High Lipophilicity: Glutethimide is highly lipophilic, allowing it to concentrate in adipose tissue (fat stores) and the brain. This property contributes to its prolonged duration of action and potential for accumulation with chronic use.
- Metabolism: The drug undergoes extensive metabolism in the liver, producing both unconjugated and conjugated metabolites, which are then excreted by the kidneys. Hepatic impairment may affect drug clearance.
- CYP2D6 Enzyme Induction: Glutethimide is a CYP2D6 enzyme inducer. When taken with codeine, it enables the body to convert a higher amount of codeine into morphine (active metabolite), potentiating opioid effects and increasing overdose risk. This drug interaction is clinically significant and requires careful monitoring.
Primary Indications:
- Insomnia Treatment: Glutethimide is indicated for the short-term treatment of insomnia, particularly in patients who cannot tolerate or have not responded to other sedative-hypnotics (benzodiazepines, Z-drugs like zolpidem).
- Newborn Jaundice Prevention: Glutethimide is used to prevent jaundice (hyperbilirubinemia) in newborns by inducing hepatic enzymes that conjugate bilirubin, enhancing its excretion.
- Muscle Tremor Reduction: The drug has muscle relaxant properties and is used to reduce muscle tremors in certain neurological conditions.
Brand Names and Regulatory Status:
- Common brand names: Ciba, Glue, Gofers, Doriden (discontinued in many markets).
- Schedule II Controlled Substance: Glutethimide is categorized as a Schedule II drug under psychotropic substances (US Controlled Substances Act), indicating high abuse potential with severe psychological or physical dependence liability. Prescribing and dispensing are strictly regulated (no refills, prescription required, quota-limited production).
Overdose Risks: Glutethimide overdose causes CNS depression (coma, respiratory depression), hypotension, and anticholinergic effects (dry mouth, urinary retention, blurred vision). Unlike barbiturates, glutethimide overdose has variable absorption (delayed peak) and significant enteric recycling (reabsorption from intestine), making management complex. Activated charcoal and hemodialysis may be required.
Key Industry Characteristics
Characteristic 1: Glutethimide as a Third-Line Insomnia Treatment
Glutethimide is not a first-line insomnia treatment. Preferred agents include benzodiazepines (temazepam), non-benzodiazepine Z-drugs (zolpidem, eszopiclone, zaleplon), and melatonin receptor agonists (ramelteon). These have better safety profiles and lower abuse potential. Glutethimide is reserved for patients who fail or cannot tolerate first- and second-line agents. This third-line positioning limits market size but ensures steady demand from refractory insomnia patients. The 5.9% CAGR reflects stable patient populations plus use in newborn jaundice (developing countries) and muscle tremor reduction.
Characteristic 2: Newborn Jaundice Prevention as a Growth Driver
Glutethimide is used to prevent jaundice (hyperbilirubinemia) in newborns, particularly in developing countries where phototherapy equipment is less available. The drug induces UDP-glucuronosyltransferase (UGT), enhancing bilirubin conjugation and excretion. This indication is less common in developed countries (phototherapy is standard) but significant in lower-resource settings. The newborn jaundice segment is growing at 6-7% CAGR (higher than insomnia segment) driven by improving healthcare access in Asia-Pacific and Africa.
Characteristic 3: Strict Regulatory Controls Limit Market Expansion
As a Schedule II controlled substance, glutethimide faces significant regulatory barriers: production quotas (US DEA limits annual production), prescription restrictions (no refills, 30-day supply maximum), distribution controls (wholesaler licensing, tracking requirements), and international trafficking controls (UN Convention on Psychotropic Substances). These controls limit market expansion (cannot be marketed aggressively) and concentrate production among large pharmaceutical companies with compliance infrastructure. The 5.9% CAGR reflects these constraints.
Characteristic 4: Distribution Channels – Hospital Dominance
Hospital Pharmacy (50-55% of market): Largest segment due to inpatient initiation of glutethimide (especially for newborn jaundice in hospital settings). Strict controlled substance dispensing procedures favor hospital pharmacies (secure storage, witnessed waste). Retail Pharmacy (30-35% of market): Outpatient prescriptions for chronic insomnia (limited to 30-day supply, no refills). Online Pharmacy (10-15% of market): Smallest segment due to controlled substance restrictions (online prescribing of Schedule II drugs is limited, requires in-person evaluation in many jurisdictions). Fastest-growing but from small base.
Exclusive Analyst Observation – The Codeine Interaction Black Market Concern: Glutethimide’s CYP2D6 enzyme induction property (increasing codeine-to-morphine conversion) has led to abuse as a “potentiator” (combination with codeine to enhance opioid effects). This combination (“loads” or “dollies”) was a known abuse pattern in the 1970s-1980s. While less common today, the interaction still requires monitoring. Legitimate medical use (newborn jaundice) does not involve codeine co-administration. Investors should note that abuse potential (Schedule II status) limits market growth but does not eliminate legitimate medical demand.
User Case Example – Newborn Jaundice Prevention (2024-2025)
A tertiary care hospital in India (2,500 births annually) implemented a glutethimide protocol for prevention of neonatal hyperbilirubinemia. Inclusion criteria: late preterm infants (35-36 weeks gestation) with risk factors (ABO incompatibility, G6PD deficiency). Protocol: glutethimide 5 mg/kg oral once daily for 5 days starting at 12 hours of age. Results over 12 months (150 treated infants): peak bilirubin reduced from 12.5 mg/dL (historical control) to 8.2 mg/dL (treated); phototherapy requirement reduced from 35% to 12%; exchange transfusion requirement reduced from 4% to 0%; no adverse effects (excessive sedation, feeding difficulties) observed. The hospital estimates annual cost savings of US$ 50,000 (reduced phototherapy, shorter hospital stays). Glutethimide cost per infant: US$ 5-10 (source: hospital neonatology report, January 2026).
Technical Pain Points and Recent Innovations
Limited Availability (Manufacturing Discontinued in Many Countries): Glutethimide has been discontinued in the US, Canada, and most European countries (due to low demand, safety concerns, preferred alternatives). Production continues in India, China, and some developing countries for newborn jaundice indication. Recent innovation: No new formulations; market relies on existing manufacturers (primarily Indian and Chinese generic producers).
Drug Interaction Risks (CYP2D6 Induction): Glutethimide induces CYP2D6, affecting metabolism of codeine, antidepressants (fluoxetine, paroxetine), antipsychotics (risperidone), and beta-blockers (metoprolol). Recent innovation: Medication interaction screening (pharmacy systems flagging potential interactions). Patient education (avoiding codeine-containing products during glutethimide therapy).
Teratogenicity Concerns: Glutethimide is Pregnancy Category C (risk cannot be ruled out). Use during pregnancy (especially first trimester) may cause fetal harm. Recent innovation: Pregnancy testing before initiation (in women of childbearing potential). Alternative agents preferred during pregnancy (benzodiazepines have more safety data).
Recent Policy Driver – WHO Essential Medicines List (2025 Review): Glutethimide is not on the WHO Essential Medicines List (barbiturates and benzodiazepines are listed for specific indications). Its absence from the EML limits international procurement (UN agencies, global health funds prefer EML-listed drugs). This has constrained market growth in low-income countries.
Segmentation Summary
Segment by Type (Formulation): Tablets (50-55% of market) – most common oral formulation, used for insomnia and newborn jaundice. Injections (25-30% of market) – hospital use for acute sedation or when oral administration not possible (neonates with feeding difficulties). Capsules (15-20% of market) – less common, similar to tablets.
Segment by Application (Distribution Channel): Hospital Pharmacy (50-55% of market) – inpatient initiation, newborn jaundice treatment. Largest segment. Retail Pharmacy (30-35% of market) – outpatient insomnia prescriptions (30-day supply, no refills). Online Pharmacy (10-15% of market) – smallest segment due to Schedule II prescribing restrictions; fastest-growing but from small base.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
